<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554799</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_MMV390048_15_01</org_study_id>
    <nct_id>NCT02554799</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Exploratory Study to Evaluate the Pharmacokinetics of Selected Oral Formulations of MMV390048 Administered in the Fasted State to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in a single centre, as an open single dose two parallel cohorts
      design with oral doses of MMV390048 administered in healthy male and female subjects between
      18 to 55 years of age. Subjects will be screened within 28 days prior to entering the study.
      On Day 1 of the study each subject will receive one of the two MMV390048 prototype
      formulations, at a dose of 40 mg with 240 mL of water. Subjects will be discharged on Day 3
      after 48h post-dose and they will attend the unit for follow-up visits on Days 5, 7, 10, 14,
      19, 26 and 29.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 exploratory study to evaluate the pharmacokinetics of selected oral formulations of
      MMV390048 administered in healthy volunteers. It is anticipated that eighteen (18) healthy
      male and female subjects are to be included in the study, however there is an option to
      include an additional cohort of 9 subjects. The optional cohort would receive a single dose
      of the formulation considered to have the least pharmacokinetic variability with a suitable
      safety and tolerability profile with food or milk. Timing of PK samples may be adjusted in
      accordance with evolving data and dosing schedule. Additional or fewer PK samples may be
      taken in accordance with evolving data and dosing schedule to establish full protocol
      specific PK profile. The study specific maximum blood volume taken will not be exceeded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">October 28, 2015</completion_date>
  <primary_completion_date type="Actual">October 28, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Peak Plasma Concentration</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Maximum concentration (Cmax) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach Peak Plasma Concentration</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Time to reach maximum plasma concentration (Tmax) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity</measure>
    <time_frame>From Pre-dose to 672 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Terminal elimination half-life (t1/2) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (Lambda z)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Terminal elimination rate constant (lambda z) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Plasma Clearance (CL/F)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Oral plasma clearance (CL/F) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Apparent volume of distribution (Vz/F) of two MMV390048 prototype formulations administered in the fasted state</description>
  </primary_outcome>
  <other_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: Time to reach maximum plasma concentration of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: Area under the plasma concentration-time curve from zero to infinity of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <other_outcome>
    <measure>Terminal Elimination Half-life</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: Terminal elimination half-life of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <other_outcome>
    <measure>Terminal Elimination Rate Constant</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: terminal elimination rate constant of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <other_outcome>
    <measure>Oral Plasma Clearance</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: Oral plasma clearance of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Volume of Distribution</measure>
    <time_frame>Up to 672 hours post-dose</time_frame>
    <description>Exploratory: Apparent volume of distribution of one MMV390048 prototype formulation administered with food or milk</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>40 mg MMV390048 tablet formulation A fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MMV390048 tablet formulation A, in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg MMV390048 tablet formulation B fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg MMV390048 tablet formulation B fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg MMV390048 formulation A or B, with milk or fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMV390048 formulation A</intervention_name>
    <description>MMV390048 formulation A, tablet</description>
    <arm_group_label>40 mg MMV390048 formulation A or B, with milk or fasted</arm_group_label>
    <arm_group_label>40 mg MMV390048 tablet formulation A fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMV390048 formulation B</intervention_name>
    <description>MMV390048 formulation B, tablet</description>
    <arm_group_label>40 mg MMV390048 formulation A or B, with milk or fasted</arm_group_label>
    <arm_group_label>40 mg MMV390048 tablet formulation B fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female (non-childbearing potential) of any race, aged 18 to 55 years

          -  body weight at least 50kg and a body mass index 18 to 30Kg/m2

          -  Females must be of non-childbearing potential:

               -  Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months
                  without an alternative medical cause with a screening follicle stimulating
                  hormone level &gt;25IU/L (for post-menopause).

               -  Premenopausal with irreversible surgical sterilization by hysterectomy

               -  and/or bilateral oophorectomy or salpingectomy at least 6 months before screening

          -  Males agree to use acceptable methods of contraception if the male subject's partner
             could become pregnant from the time of study medication until 120 days after
             administration of study medication. One of the following acceptable methods of
             contraception must be used:

               -  Condom and occlusive cap (diaphragm or cervical/vault cap) with spermicidal
                  foam/gel/film/cream/suppository

               -  Surgical sterilization (vasectomy with documentation of azoospermia) and an
                  acceptable barrier method (condom or occlusive cap [diaphragm or cervical/vault
                  cap] used with spermicidal foam/gel/film/cream/suppository)

               -  subject's female partner uses oral contraceptives (combination estrogen /
                  progesterone pills), injectable progesterone or sub-dermal implants and an
                  acceptable barrier method

               -  subject's female partner uses medically prescribed topically applied transdermal
                  contraceptive patch and an acceptable barrier method

               -  subject's female partner has undergone documented tubal ligation (female
                  sterilization). In addition, an acceptable barrier method must be used.

               -  subject's female partner has undergone documented placement of an intrauterine
                  device or intrauterine system. In addition, an acceptable barrier method must be
                  used.

               -  True abstinence: when in line with the preferred and usual lifestyle of the
                  subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception. Abstinent subjects have to agree to use 1 of the above-mentioned
                  contraceptive methods, if they start sexual relationships during the study and
                  for up to 120 days post-study drug

          -  non-smokers or ex-smokers for more than 90 days prior to screening or smoke no more
             than 5 cigarettes per day. If users of nicotine products (spray, patch, e-cigarette,
             etc.) they should use the equivalent of no more than 5 cigarettes /day

          -  Subjects should not donate egg or sperm from the time of administration of study
             medication until 120 days post-study drug

          -  capable of fully understanding and complying with the requirements of the study and
             must sign the informed consent form prior to undergoing any study-related procedures

          -  agree to avoid excessive UV radiation exposure (occupational exposure to the sun,
             sunbathing, tanning salon use, phototherapy, etc.) throughout the study.

        Exclusion Criteria:

          -  Male subjects with a female partner(s) who is (are) pregnant or lactating from the
             time of study medication

          -  Women of childbearing potential, defined as all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle, or sexual orientation
             precludes intercourse with a male partner and women whose partners have been
             sterilized by vasectomy or other means

          -  Current or recurrent disease (e.g. cardiovascular, neurological, renal,
             gastrointestinal, oncologic or other conditions) that may affect the action,
             absorption or disposition of the study medication or could affect clinical assessments
             or clinical laboratory evaluations

          -  Current or relevant history of physical or psychiatric illness that may require
             treatment or make the subject unlikely to fully comply with the requirements or
             complete the study, or any condition that presents undue risk from the investigational
             product or study procedures

          -  Any other significant disease or disorder which, in the opinion of the investigator,
             may either put the subject at risk because of the participation in the study, may
             influence the result of the study, or the subject's ability to participate in the
             study

          -  History of photosensitivity

          -  History or clinical evidence of alcohol or substance abuse. Alcohol abuse is defined
             as regular weekly intake of more than 21 units for males and 14 units for females

          -  Any clinically relevant history of intolerance/allergy to milk or dairy products

          -  Use of an investigational product or participation in a clinical study within 90 days
             before study medication

          -  Donation of blood products or of more than 500ml of blood in 90 days prior to study
             medication

          -  Use of any prescription drugs within 14 days or within 5 times the elimination
             half-life (whichever period is longer) prior to study medication

          -  Use moderate or strong inhibitors and/or inducers of CYP450/Transporters within 4
             weeks prior to study drug administration (or 5 half-lives of the compound if longer)

          -  Use of over-the-counter medications or dietary supplements, including vitamins and
             herbal supplements within 7 days of study drug. With the exception of paracetamol
             which may be used incidentally or for short-term treatment at a maximum of 2g/day

          -  Intake of grapefruit, grapefruit juice or other products containing grapefruit within
             28 days prior to study drug

          -  Excessive intake of caffeine drinks or energy drinks within 48 hours before admission
             (more than three 250ml cups of coffee a day, equivalent to roughly 250mg caffeine)

          -  Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations at
             screening or admission.

          -  Any liver function tests elevated &gt;1.5 times the upper limit of normal, considered by
             the investigator as clinically relevant, at screening or admission

          -  Abnormal serum Hemoglobin, Haptoglobin, Reticulocyte count or Lactate Dehydrogenase at
             screening/admission

          -  abnormal ECG results at screening/admission results considered as clinically
             significant by the investigator

          -  Confirmed positive urine drug screen (amphetamines, benzodiazepines, cocaine,
             cannabinoids, opiates, barbiturates or methadone) or from the alcohol breath test at
             screening/admission.

          -  positive human immunodeficiency virus, hepatitis B surface antigen, anti Hepatitis
             core antibody, or hepatitis C virus antibody at screening

          -  veins unsuitable for intravenous puncture or cannulation on either arm (e.g. veins
             difficult to locate, access or puncture, veins with a tendency to rupture during or
             after puncture) 23. Any conditions which in the opinion of the investigator would make
             the subject unsuitable for enrolment or could interfere with the subjects'
             participation in or completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd.</name>
      <address>
        <city>Croydon</city>
        <state>London</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Optional Cohort:
The study design of this clinical trial allowed for an optional cohort to be enrolled. Ultimately, such optional cohort was not deemed required and therefore not conducted.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>40 mg MMV390048 Form A Fasted</title>
          <description>40 mg MMV390048 tablet formulation A fasted</description>
        </group>
        <group group_id="P2">
          <title>40 mg MMV390048 Form B Fasted</title>
          <description>40 mg MMV390048 tablet formulation B fasted</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>40 mg MMV390048 Form A Fasted</title>
          <description>40 mg MMV390048 tablet formulation A fasted</description>
        </group>
        <group group_id="B2">
          <title>40 mg MMV390048 Form B Fasted</title>
          <description>40 mg MMV390048 tablet formulation B fasted</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="10.37"/>
                    <measurement group_id="B2" value="26" spread="11.5"/>
                    <measurement group_id="B3" value="28.5" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Peak Plasma Concentration</title>
        <description>Maximum concentration (Cmax) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Peak Plasma Concentration</title>
          <description>Maximum concentration (Cmax) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="62.5"/>
                    <measurement group_id="O2" value="373.4444" spread="64.7825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach Peak Plasma Concentration</title>
        <description>Time to reach maximum plasma concentration (Tmax) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach Peak Plasma Concentration</title>
          <description>Time to reach maximum plasma concentration (Tmax) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.01"/>
                    <measurement group_id="O2" value="2.6" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity</title>
        <description>Area under the plasma concentration-time curve (AUC) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>From Pre-dose to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity</title>
          <description>Area under the plasma concentration-time curve (AUC) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56991.64" spread="39197.535"/>
                    <measurement group_id="O2" value="63228.3" spread="29689.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (t1/2)</title>
        <description>Terminal elimination half-life (t1/2) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2)</title>
          <description>Terminal elimination half-life (t1/2) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.0663" spread="90.5336"/>
                    <measurement group_id="O2" value="160.3984" spread="61.3228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Rate Constant (Lambda z)</title>
        <description>Terminal elimination rate constant (lambda z) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (Lambda z)</title>
          <description>Terminal elimination rate constant (lambda z) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>1/hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0041" spread="0.0011"/>
                    <measurement group_id="O2" value="0.0051" spread="0.0024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Plasma Clearance (CL/F)</title>
        <description>Oral plasma clearance (CL/F) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Plasma Clearance (CL/F)</title>
          <description>Oral plasma clearance (CL/F) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>L/hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8819" spread="0.3473"/>
                    <measurement group_id="O2" value="0.7635" spread="0.3658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F)</title>
        <description>Apparent volume of distribution (Vz/F) of two MMV390048 prototype formulations administered in the fasted state</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40 mg MMV390048 Form A Fasted</title>
            <description>40 mg MMV390048 tablet formulation A fasted</description>
          </group>
          <group group_id="O2">
            <title>40 mg MMV390048 Form B Fasted</title>
            <description>40 mg MMV390048 tablet formulation B fasted</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F)</title>
          <description>Apparent volume of distribution (Vz/F) of two MMV390048 prototype formulations administered in the fasted state</description>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.9523" spread="45.8906"/>
                    <measurement group_id="O2" value="155.3750" spread="49.9488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax)</title>
        <description>Exploratory: Time to reach maximum plasma concentration of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC)</title>
        <description>Exploratory: Area under the plasma concentration-time curve from zero to infinity of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Terminal Elimination Half-life</title>
        <description>Exploratory: Terminal elimination half-life of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Terminal Elimination Rate Constant</title>
        <description>Exploratory: terminal elimination rate constant of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Oral Plasma Clearance</title>
        <description>Exploratory: Oral plasma clearance of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Volume of Distribution</title>
        <description>Exploratory: Apparent volume of distribution of one MMV390048 prototype formulation administered with food or milk</description>
        <time_frame>Up to 672 hours post-dose</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 672 hours post-dose (=study completion)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>40 mg MMV390048 Form A Fasted</title>
          <description>40 mg MMV390048 tablet formulation A fasted</description>
        </group>
        <group group_id="E2">
          <title>40 mg MMV390048 Form B Fasted</title>
          <description>40 mg MMV390048 tablet formulation B fasted</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Richmond Pharmacology Limited (RPL) shall not issue or submit any press release for publication without MMV's prior written approval.
In recognition that RPL and the Site Principal Investigator have a responsibility to ensure that results of scientific interest arising from a Clinical Trial are appropriately published and disseminated, RPL may, upon MMV's written consent which will not be unreasonably withheld, publish Results of a clinical trial carried out under a Project Agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cristina Donini</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0312</phone>
      <email>doninic@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

